// App-Quantinova.ai

AB0813 : GUSELKUMAB-TREATED PATIENTS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC SYMPTOMS AS MEASURED WITH PROMIS INSTRUMENT: RESULTS FROM PHASE-3 PSORIATIC ARTHRITIS TRIAL DISCOVER 1

Researchers

Presenter

  • A. M. Orbai

Principal Investigators

  • L. C. Coates

  • A. Deodhar

  • P. Helliwell

  • C. T. Ritchlin

  • A. Kollmeier

  • E. C. Hsia

  • X. L. Xu

  • S. Sheng

  • B. Zhou

  • C. Han

Medical Centers

  • Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, United States of America

  • Stroke, Oxford Univ Hosps, Oxford, United Kingdom

  • Oregon Health & Science Univ, Portland, United States

  • University of Leeds, Leeds, United Kingdom

  • U Rochester Med Ctr, Rochester, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Perelman School of Medicine, Philadelphia, United States of America

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Depression

  • Inflammatory Arthritis

  • Anxiety

Biomarkers

  • Nutritional risk screening

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03162796

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved